Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of “Buy” by Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have received a consensus recommendation of “Buy” from the nine brokerages that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $20.83.

STOK has been the subject of several recent analyst reports. Leerink Partners began coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price for the company. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 6th.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the completion of the sale, the insider now owns 51,277 shares of the company’s stock, valued at $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the completion of the transaction, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. This represents a 8.24 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,000,349 shares of company stock valued at $28,031,296. 11.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Quest Partners LLC acquired a new stake in Stoke Therapeutics during the second quarter worth about $29,000. Nisa Investment Advisors LLC grew its stake in shares of Stoke Therapeutics by 53.2% in the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $123,000. Intech Investment Management LLC acquired a new position in shares of Stoke Therapeutics during the 3rd quarter valued at $160,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares during the period.

Stoke Therapeutics Price Performance

STOK stock opened at $12.98 on Thursday. The company has a market cap of $687.55 million, a price-to-earnings ratio of -6.18 and a beta of 0.95. The company has a fifty day moving average price of $12.46 and a 200 day moving average price of $13.68. Stoke Therapeutics has a 12 month low of $4.09 and a 12 month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, analysts anticipate that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.